Online inquiry

IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3423MR)

This product GTTS-WQ3423MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets HGF gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000601.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3082
UniProt ID P14210
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3423MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3179MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ10953MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MBG-453
GTTS-WQ14465MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ5368MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ3966MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ6563MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DC-1630423
GTTS-WQ3648MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ2585MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 531
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW